Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Lung Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Thoracic Neoplasm
Lung Neoplasm

Cancer Family

Lung Neoplasm

CI-CAN-00000221Explore in graph →

Non-malignant2,726 active trials51 approved drugs619 evidence items

NCIt: C3200
MeSH: D008175

Overview
Statistics
Survival
Genomics41
Variants & evidence619
Drugs128
Trials11603
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (483)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 351–375 of 483 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature.
· Lung Cancer · 2022 · PMID 35245845 · validated civic_curation pubmed
A Novel KIF5B-EGFR Fusion Variant in Non-Small-Cell Lung Cancer and Response to Afatinib: A Case Report.
· Onco Targets Ther · 2021 · PMID 34163176 · validated civic_curation pubmed
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.
· JCO Precis Oncol · 2022 · PMID 35085007 · validated civic_curation pubmed
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
· Cancer Discov · 2021 · PMID 33004339 · validated civic_curation pubmed
EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?
· J Thorac Oncol · 2018 · PMID 29472054 · validated civic_curation pubmed
EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature.
· Transl Lung Cancer Res · 2022 · PMID 35399574 · validated civic_curation pubmed
Adenocarcinoma Harboring EGFR-RAD51 Fusion Treated With Osimertinib: A Case Report.
· JTO Clin Res Rep · 2024 · PMID 38525318 · validated civic_curation pubmed

Showing 351–375 of 483 publications

← Previous
1
…
14
15
16
…
20
Next →

Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report.

· Heliyon · 2023 · PMID 38074875 · validated civic_curation pubmed

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.

· J Thorac Oncol · 2013 · PMID 23524406 · validated civic_curation pubmed

A patient with lung adenocarcinoma and RET fusion treated with vandetanib.

· J Thorac Oncol · 2013 · PMID 23584301 · validated civic_curation pubmed

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.

· Nat Med · 2014 · PMID 24836576 · validated civic_curation pubmed

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations.

· J Thorac Oncol · 2016 · PMID 26724472 · validated civic_curation pubmed

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.

· Lung Cancer · 2014 · PMID 24192513 · validated civic_curation pubmed

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.

· BMC Cancer · 2012 · PMID 23181703 · validated civic_curation pubmed

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

· J Clin Oncol · 2010 · PMID 20940188 · validated civic_curation pubmed

Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).

· Jpn J Clin Oncol · 2010 · PMID 20522446 · validated civic_curation pubmed

RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.

· Cancer Discov · 2015 · PMID 26370156 · validated civic_curation pubmed

Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.

· J Thorac Oncol · 2014 · PMID 25393796 · validated civic_curation pubmed

Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity.

· Ann Oncol · 2016 · PMID 26787234 · validated civic_curation pubmed

Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.

· Lung Cancer · 2015 · PMID 25982012 · validated civic_curation pubmed

Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.

· J Thorac Oncol · 2016 · PMID 26845194 · validated civic_curation pubmed

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.

· J Thorac Oncol · 2016 · PMID 27343442 · validated civic_curation pubmed

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.

· J Thorac Oncol · 2017 · PMID 27664533 · validated civic_curation pubmed

EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.

· Ann Oncol · 2015 · PMID 26269204 · validated civic_curation pubmed

S768I Mutation in EGFR in Patients with Lung Cancer.

· J Thorac Oncol · 2016 · PMID 27211795 · validated civic_curation pubmed